Back to top

Image: Bigstock

Quest Diagnostics Inc.

Read MoreHide Full Article

Ahead of second quarter earning, Quest Diagnostics saw upward estimate revision on another consecutive quarter of organic growth expectation. Keeping in line with its five-point strategy, Quest Diagnostics is refocusing on core diagnostic information services business through product launch and strategic alliances and is also working on delivering disciplined capital deployment. We are looking forward to the company’s recent partnerships with Safeway and HealthOne Systems of HCA Healthcare. We are also encouraged about the company’s newly launched three cancer tests that will provide clinically actionable insight into an individual's risk of developing hereditary cancer. Most importantly, after suffering through several quarters of low volume environment, the company has finally witnessed a nice sequential improvement in terms of both volume and pricing. However, sustainability of this improvement is still a matter of question.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Quest Diagnostics Incorporated (DGX) - free report >>

Published in